Inhibitors that act mainly on MAO-A (harmine and harmaline) are used in the treatment of depression, due to their ability to raise serotonin concentrations, while inhibitors of MAO-B decrease dopamine degradation and improve motor control in patients with Parkinson’s disease (Repic et al., 2014). The gene discussed is MAOA; the disease is Parkinson disease.